Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | Daratumumab consolidation therapy in MM

Alessandro Gozzetti • 14 Sep 2019
IMW 2019
Multiple Myeloma Daratumumab

Alessandro Gozzetti, MD, PhD, Sense University Hospital, Siena, Italy, discusses the use of daratumumab as consolidation therapy, in particular after autologous STEM cell transplantation in multiple myeloma (MM) patients, speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Alessandro Gozzetti

Treating transplant-ineligible patients with myeloma in Italy
1:29
Treating transplant-ineligible patients with myeloma in Italy
Alessandro Gozzetti • 27 Sep 2024
Final results of the DART4MM study of daratumumab for MRD eradication in myeloma
2:42
Final results of the DART4MM study of daratumumab for MRD eradication in myeloma
Alessandro Gozzetti • 27 Sep 2024
Early relapse prediction in myeloma treated with novel agents
1:31
Early relapse prediction in myeloma treated with novel agents
Alessandro Gozzetti • 24 Feb 2021
FORTE: MRD negativity as key prognostic factor in NDMM
1:37
FORTE: MRD negativity as key prognostic factor in NDMM
Alessandro Gozzetti • 24 Feb 2021

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Alessandro Gozzetti • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Alessandro Gozzetti • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Alessandro Gozzetti • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Alessandro Gozzetti • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals